FOLD Amicus Therapeutics Inc.

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025

PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September.

  • Cantor Global Healthcare Conference 2025 in New York, NY, on Wednesday, September 3, 2025, at 10:20 a.m. ET
  • Morgan Stanley 23rd Annual Global Healthcare Conference 2025 in New York, NY on Tuesday, September 9, 2025, at 3:20 p.m. ET

A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at .

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at , and follow on and .

CONTACT:

Investors:

Amicus Therapeutics

Andrew Faughnan

Vice President, Investor Relations



(609) 662-3809

Media:

Amicus Therapeutics

Diana Moore

Vice President, Corporate Communications



(609) 662-5079

FOLD–G



EN
29/08/2025

Underlying

FOLDAmicus Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amicus Therapeutics Inc.

 PRESS RELEASE
Free
FOLD Amicus Therapeu...

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® ...

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda® PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), today announced the presentation of new 4-year muscle function, muscle strength and biomarker endpoints from the PROPEL open-label extension (OLE) study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) at the International Congress of Inborn Errors of M...

12h / 28m 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics to Present at Upcoming Investor Conferences in Sep...

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Cantor Global Healthcare Conference 2025 in New York, NY, on Wednesday, September 3, 2025, at 10:20 a.m. ETMorgan Stanley 23rd Annual Global Healthcare Conference 2025 in New York, NY on Tuesday, September 9, 2025, at 3:20 p.m. ET A live audio webcast of each presentation can also be accessed via ...

August 29, 2025 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics Announces Second Quarter 2025 Financial Results an...

Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold® Q2 Revenue of $128.9M, up 12% at CER Pombiliti® + Opfolda® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance including GAAP Profitability During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, tod...

July 31, 2025 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics to Announce Second Quarter 2025 Financial Results ...

Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, July 31, 2025, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2025. Participants and investors interested in accessing the call by phone will need to register using the . After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event...

July 21, 2025 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase ...

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in Japan for Adults with Late-onset Pompe Disease (LOPD) PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for the treatment of adult patients with late-onset Pompe disease (LOPD). "We are delighted that we will now be able to offer a compel...

June 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch